Bimzelx is an injectable medication used to treat certain types of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy [1]. It is also indicated for adults with active psoriatic arthritis who have had an inadequate response or intolerance to other disease-modifying antirheumatic drugs [1].
What is Bimzelx and How Does It Work?
Bimzelx, with the active ingredient bimekizumab, is a monoclonal antibody [1]. It targets and inhibits interleukin-17A (IL-17A) and interleukin-17F (IL-17F) cytokines [1]. These cytokines are key drivers of inflammation in conditions like psoriasis and psoriatic arthritis [1]. By blocking these specific interleukins, Bimzelx helps to reduce inflammation and the associated symptoms of these diseases [1].
What Conditions Does Bimzelx Treat?
Bimzelx is approved for the treatment of adults with:
* Moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy [1].
* Active psoriatic arthritis who have had an inadequate response or intolerance to other disease-modifying antirheumatic drugs (DMARDs) [1].
What Are the Dosing Instructions for Bimzelx?
The recommended dose of Bimzelx for plaque psoriasis is 320 mg administered subcutaneously at weeks 0, 4, 8, 12, and 16, followed by 320 mg every 8 weeks thereafter [1]. For psoriatic arthritis, the recommended dose is also 320 mg subcutaneously at weeks 0, 4, 8, 12, and 16, followed by 320 mg every 8 weeks [1]. Each 320 mg dose is typically given as two 160 mg injections [1].
What Are the Potential Side Effects of Bimzelx?
Common side effects reported with Bimzelx include upper respiratory tract infections, headache, and reactions at the injection site [1]. It can also increase the risk of infections, including serious ones [1]. Patients should discuss their medical history with their healthcare provider before starting Bimzelx, as it may not be suitable for everyone [1].
When Does Bimzelx Patent Protection End?
Information regarding specific patent expiry dates for Bimzelx is not readily available in this context. DrugPatentWatch.com provides a resource for tracking patent information for various medications [2].
Who Manufactures Bimzelx?
Bimzelx is manufactured by UCB Pharma [1].